secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001437749-25-033948
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar presents Phase 2 data showing ALXN1840 rapidly improves copper balance in Wilson disease
--------------------------------------------------------------------------------

- Oral presentation at AASLD 2025: 'Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline.'
- Mean daily copper balance significantly improved vs. pre-treatment baseline in 8 patients on ALXN1840.
- Improvement observed during 15 mg once-daily (days 1-28) and entire treatment period (days 1-39).
- Copper balance improved primarily via increased fecal copper excretion; data available on Monopar's website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925033948/0001437749-25-033948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925033948/mnpr20251108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer